Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 12, 2026

Ridgepost Capital Reports Fourth Quarter and Full Year 2025 Earnings Results

View original at globenewswire.com
Ridgepost Capital Reports Fourth Quarter and Full Year 2025 Earnings Results Record Full Year Fundraising and Deployment of $5.1 Billion Fee-Paying AUM increased 15% year over year DALLAS, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Non-GAAP financial measures including FRR, FRE, ANI, and Fully Diluted ANI per share provide better comparability of ongoing operating performance to prior periods.

    80% confidence
  • The 2025 earnings report marks Ridgepost Capital's first under its new identity, representing platform expansion and strategy integration work done over the past few years.

    80% confidence
  • During 2025, Ridgepost Capital raised and deployed a record $5.1 billion in organic gross new fee-paying assets and exceeded initial annual organic fundraising guidance by over $1 billion.

    80% confidence
  • The Dubai office opening and CAIS collaboration will meaningfully increase Ridgepost Capital's global footprint and enable capturing of growing demand for alternatives in the wealth ecosystem.

    80% confidence
  • Total assets under management exceeded $43 billion as of December 31, 2025.

    80% confidence
  • Fee-Paying Assets Under Management increased 15% year over year to $29.4 billion as of December 31, 2025.

    80% confidence
  • The acquisition of Stellus Capital Management advances Ridgepost Capital's long-term strategy of partnering with best-in-class investment managers by adding a leading direct lending franchise.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com